Pfizer beats profit estimates on cost cuts, COVID vaccine sales
(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a smaller-than-feared drop in sales of its COVID-19 vaccine. "Our revenue volatility is largely in the past as COVID-related uncertainties have diminished,
Pfizer’s Covid boost overshadowed by Kennedy threat to vaccines
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's nomination moved forward.
Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to fend off criticism from an activist investor that has argued the company squandered its pandemic gains and needs a new path forward.
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.
Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of COVID vaccine Comirnaty and antiviral Paxlovid,
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.
Pfizer beats profit estimates on heart disease drug, COVID vaccine sales
(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a smaller-than-feared drop in sales of its COVID-19 vaccine and strong demand for its heart drug Vyndaqel.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
Pfizer exceeds Q4 earnings estimates as covid product sales outperform expectations
Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street's projections. The business also presented their financial projection for 2025.
Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations
Pfizer stock rose moderately early Tuesday as better-than-expected Covid product sales helped drive a fourth-quarter beat.
Rappler1d
FACT CHECK: Post on alleged Pfizer COVID-19 vaccine side effects is false
Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...
WBEZ6h
Johnson rescinds controversial COVID-19 vaccination mandate
The Illinois Labor Relations Board has twice ruled that the city violated employees' collective bargaining rights by failing ...
Politifact7d
No, Pfizer didn’t release a new list of COVID-19 vaccine side effects
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Pfizer's CEO says he's had dinner with Trump's health secretary pick, RFK Jr.
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
Idaho Republican pushes ban of mRNA vaccines against COVID, gene therapy products
The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
MSD shares sink 11% after vaccine shipments to China halted
Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...